Overview
Updated 14 Jul 2026
Roham Zamanian, MD, is James and Yvonne Wood Professor of Pulmonary Vascular Medicine at Stanford University School of Medicine, Department of Medicine, Division of Pulmonary, Allergy & Critical Care Medicine. The public record shows 286 publications with 10,119 citations (h-index 56), centered on Pulmonary Hypertension Research and Treatments, Cardiovascular Function and Risk Factors, Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 7 companies, 2 NIH-funded awards (2017–2025).
- Most recent indexed publication: 2026 · American journal of respiratory and critical care medicine
- Top research focus: Pulmonary Hypertension Research and Treatments
- 9 registered trials on ClinicalTrials.gov
- Open Payments reporting from 7 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 10 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 130.
Clinical & industrytrials, payments and federal funding
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:
- Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
Sponsor: Stanford University
InvestigatorPhase 2Not, yet, recruitingNCT07601295 - A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension
Sponsor: Joseph C. Wu
InvestigatorPhase 1RecruitingNCT06872112 - A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Sponsor: Novartis Pharmaceuticals
InvestigatorPhase 1/PHASE2RecruitingNCT06649110
Industry payments
Updated 14 Jul 2026
7 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202511 payments$21,225openpaymentsdata.cms.gov ↗
- United Therapeutics CorporationProgram year20258 payments$11,063openpaymentsdata.cms.gov ↗
- Actelion Pharmaceuticals US, Inc.Program year20246 payments
NIH funding
Updated 14 Jul 2026
2 NIH research awards on record, funded 2017–2025 per NIH RePORTER. The latest:
- 1/2 A Phase 2 Study of Elafin (Tiprelestat) for the Treatment of Pulmonary Arterial Hypertension (PAH)
Stanford University
FY2025$1,998,124UG3HL180990 - Case-Control Study of Methamphetamine in Pulmonary Arterial Hypertension
University of Pennsylvania
FY2025$714,004R01HL159886 - Case-Control Study of Methamphetamine in Pulmonary Arterial Hypertension
University of Pennsylvania
FY2024$683,215R01HL159886
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Identification of Pulmonary Arterial Hypertension Patients with Venous or Capillary Involvement.
American journal of respiratory and critical care medicine
2026 - Circulating Biomarker Results From a Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension.
American journal of respiratory and critical care medicine
2026 - Incident Atrial Fibrillation and Flutter in Patients With Pulmonary Arterial Hypertension: Influence of Right Ventricular Dilatation and Reduced Right Atrial Function.
Journal of the American Heart Association
2026 - Medication Nonadherence in Patients with Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry (PHAR).
Annals of the American Thoracic Society
2025
Most-cited worksby citation count (OpenAlex)
- 01
- 03Insulin resistance in pulmonary arterial hypertension275 citations2008
- 04
- 05
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
300 Pasteur Dr, A251, MC 5221, Stanford, CA 94305
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- Internal Medicine Residency
UC Irvine Medical Center (2002); Pulmonary & Critical Care Fellowship, UC Irvine Medical Center (2003) and Stanford University (2005); Super-Fellowship in Pulmonary Vascular Disease …
2005verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →stanfordhealthcare.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
Editorial & leadership rolesjournal and society appointments
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- Director
Adult Pulmonary Hypertension Service, Vera Moulton Wall Center for Pulmonary Vascular Disease, Stanford University
2007verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →stanfordhealthcare.org ↗
Awards & honorshonors on the public record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →stanfordhealthcare.org ↗
Secondary affiliationsappointments beyond the home institution
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →phaware.global ↗
- Member
Stanford Cardiovascular Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗ - Member
Wu Tsai Human Performance Alliance, Stanford University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
Media & interviewspress, podcasts and appearances
- Stanford Medicine News feature: "The two years of living dangerously: One doctor's journey to the United States" (2010)
profile/interview on his emigration story
2010verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.stanford.edu ↗ - "I'm Aware That I'm Rare: the phaware podcast"
Episode 345 (guest, on the 20th Annual Race Against PH at Stanford)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →phaware.medium.com ↗ - "I'm Aware That I'm Rare: the phaware podcast"
Episode 527, MD, FCCP (guest, discusses "disease modification" concept in PH treatment)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →phaware.medium.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- Doximity
doximity.com/pub/roham-zamanian-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/roham-zamanian-3bbbb110
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Roham-Zamanian
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Mentions by otherswhere others cite or feature them
- Other
phaware.global/whoweare
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →phaware.global ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Paul Heidenreich, MD
Stanford University
- 1,067
- publications
- 113
- h-index
- 7
- trials
Mark Pegram, MD
Stanford University
- 421
- publications
- 67
- h-index
- 11
- trials
Crystal Mackall, MD
Stanford University
- 333
- publications
- 75
- h-index
- 9
- trials
David Maron, MD
Stanford University
- 455
- publications
- 67
- h-index
- 4
- trials